Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
NCT06237452Phase 3Recruiting
- Sponsor
- Vedanta Biosciences
- Start
- May 2024
- Primary completion
- Jun 2027
- Modality
- Live Biotherapeutic Products
- Countries
- 24
01
Overview
A Phase 3 trial of VE303 in Clostridioides difficile infection (CDI), sponsored by Vedanta Biosciences. Started May 2024; status: recruiting.
02
Drugs
VE303
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT06237452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06237452.